In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 
The Grand Debate 1: Advances in medical and interventional treatment of heart failure
Session

Event : Heart Failure 2019

Topic : Chronic Heart Failure – Treatment

  • Session type : Debate Session
  • Date : 25 May 2019
  • Time : 16:45 - 18:15

10 presentations in this session

Positioning of the topic.

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : A Coats (Warwickshire,GB)

TAVI should be used in low risk patients with symptomatic severe aortic stenosis - Pro

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : A Colombo (Milan,IT)

TAVI should be used in low risk patients with symptomatic severe aortic stenosis - Con.

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : F Maisano (Zurich,CH)

TAVI should be used in low risk patients with symptomatic severe aortic stenosi - Rebuttal.

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure

Conclusion and take-home message.

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : A Coats (Warwickshire,GB)

Positioning of the topic.

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : B Bozkurt (Houston,US)

Therapy with Sacubitril-Valsartan should begin in hospital-Pro

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : E Velazquez (New Haven,US)

Therapy with Sacubitril-Valsartan should begin in hospital - Con

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : GMC Rosano (London,GB)

Therapy with Sacubitril-Valsartan should begin in hospital - Rebuttal

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : E Velazquez (New Haven,US), GMC Rosano (London,GB)

Conclusion and take-home message.

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : B Bozkurt (Houston,US)

Francesco Maisano speaker

Francesco Maisano

University Hospital Zurich, Zurich (Switzerland)
50
Antonio Colombo speaker

Antonio Colombo

EMO-GVM Heart Center Columbus, Milan (Italy)
16
Giuseppe M C Rosano speaker

Giuseppe M C Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)
50
no speaker photo speaker

Eric Velazquez

Yale University, New Haven (United States of America)
7
Andrew Coats speaker

Andrew Coats

University of Warwick, Coventry (United Kingdom of Great Britain & Northern Ireland)
66
Biykem Bozkurt speaker

Biykem Bozkurt

Baylor College of Medicine, Houston (United States of America)
5

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are